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Abstract 2 
The rhizome of Atractylodes lancea (Thunb.) DC. (AL) is extensively used in 3 
Chinese, Thai, and Japanese traditional medicines as crude extracts/decoctions or a 4 
component in various herbal formulations.  Various pharmacological activities of AL and 5 
its major constituents have been demonstrated in vitro, ex vivo, and in animal models.  6 
Results from the toxicity studies in animal models suggest safety profile of AL and its 7 
active constituents.  Despite extensive use with positive impression in many diseases, 8 
there has not been a clinical study that can conclusively support its efficacy and safety 9 
profile in human.  This review comprehensively summarizes current information on the 10 
pharmacological activities of AL and their active constituents including anticancer, anti-11 
inflammatory, antimicrobial and antipyretic activities, as well as activities on central 12 
nervous, cardiovascular, and gastrointestinal systems.  13 
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1. Introduction 24 
According to the World Health Organization (WHO) report in 2011 [1], traditional 25 
medicine addresses up to two-third of the world’s population’s primary health care needs.  26 
One major component of traditional medicine is the use of herbal medicine.  A common 27 
issue of herbal medicine is the limitation of information on their pharmacological activities 28 
and their constituents.  Traditionally, the use of herbal medicine was based on empirical 29 
treatment and then passed on from generation to generation.  In the past 20 years, there 30 
were more studies on pharmacological activities and the constituents of many herbal 31 
medicines, but the information is often published in local journals and is not extensively 32 
disseminated.  The limited access to these information prevented many herbal medicines 33 
from being developed to their full potential. 34 
The rhizome of Atractylodes lancea (Thunb.) DC. (AL) has been used widely in 35 
many countries for various indications.  This compound is called “Cangzhu” in China, 36 
“Khod-Kha-Mao” in Thailand, and “So-jutsu” in Japan.  In Chinese traditional medicine, 37 
this rhizome is used extensively for the treatment of several diseases such as rheumatic 38 
diseases, digestive disorders, night blindness, and influenza.  These traditional uses are 39 
explained by the compound’s ability to eliminate dampness, strengthen the spleen, expel 40 
wind-cold from the superficial parts of the body, and clear away the common cold [2].  In 41 
Thai traditional medicine, the dried rhizome of AL has been used to treat fever and the 42 
common cold [3].  Moreover, it has also been used as a component in Thai traditional 43 
medicine in order to relieve gastrointestinal symptoms including dyspepsia, flatulence, 44 
nausea, and noninfectious diarrhea.  In Japan, the rhizome of AL is a component in 45 
several Kampo medicines, e.g., Juzen-taiho-to [4] and Saireito [5,6]. 46 
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History of extensive use of this herb in mankind has facilitated the development of 47 
this herb to its full therapeutic potential.  This has brought about this review article, whose 48 
purpose is to aid the readers in gaining a better understanding of the potential and toxicity 49 
of this medicinal plant and to contribute to appropriate decision-making in further 50 
development of AL.  This review article will focus on the pharmacological activities of the 51 
crude extract of AL rhizome including its major constituents: β-eudesmol, hinesol, 52 
atractylone and atractylodin [7-9]. 53 
 54 
2. The pharmacological activities of Atractylodes lancea (Thunb.) DC. 55 
2.1 Anticancer activities 56 
Several conventional anticancer drugs being used in patients with cancers are 57 
derived from plants.  These include Vinblastine, Vincristine, Etoposide, Teniposide, 58 
Paclitaxel, Vinorelbine, Docetaxel, Topotecan, and Irinotecan, all of which have been 59 
approved  by the US Food and Drug Administration [10].  Moreover, there are several 60 
herbal medicines of which their promising anticancer activities were demonstrated in 61 
laboratory experiments and clinical trials [11].  Recently, it appears that the rhizome of AL 62 
is a promising candidate herbal plant for further development as anticancer drugs, 63 
particularly as an alternative treatment in patients with cholangiocarcionma (CCA), the 64 
cancer of bile duct.    65 
The anticancer activities of AL particularly anti-CCA have been demonstrated in 66 
several studies both in vitro and in vivo.  Of a total of 28 plants and 5 herbal formulations 67 
used in Thai traditional medicine investigated for their cytotoxic activities, the crude 68 
ethanolic extract of AL rhizome was shown to exhibit the most potent and selective 69 
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activity against CCA cell line (CL-6) with IC50 (concentration which inhibits cell growth by 70 
50%) of 24.09±3.40 (mean±SD) µg/ml and SI (selectivity index) of 8.6 [12].  Results of the 71 
in vitro screening of tumoricidal properties of international medicinal herbs conducted in 72 
the United States also confirmed the anticancer activity of AL in murine neuroblastoma 73 
cells originally derived from a spontaneous malignant tumor with moderate to strong 74 
activity with LC50 (50% lethal concentration, the concentration which causes 50% cell 75 
death) of 0.704 mg/ml [13].  These two studies have caught researchers’ attentions to 76 
further investigate the anticancer property of AL.  Based on calcein-AM and Hoechst 77 
33342 assays, the cytotoxic activity of the ethanolic extract of AL against CL-6 was found 78 
to be more potent and more selective than the standard anticancer 5-fluorouracil (5-FU) 79 
[14].  Additionally, AL also exhibited significant inhibitory effects on clonogenic survival, 80 
tube formation, and invasion of CL-6 cells through a basement membrane model in a 81 
dose-dependent manner.  However, this compound did not significantly exhibit 82 
antioxidative activity determined by the radical-scarvenging activity of 2,2-diphenyl-1-83 
picrylhydrazyl radical (DPPH).  With regards to antitumoric property of AL in animal 84 
models, the ethanolic extract at the concentrations of 1,000, 3,000, and 5,000 mg/kg 85 
body weight significantly inhibited tumor growth in CCA-xenografted nude mice [15].  The 86 
tumor size of AL-treated group was reduced to about 10% of that in the control group on 87 
day 40 after treatment (mean±SD: tumor volumes: 550±13 and 20,661±126 mm3 for  AL-88 
treated and control group, respectively).  At the highest dose of 5,000 mg/kg body weight, 89 
AL significantly inhibited lung metastasis by about 95%, while in the control group lung 90 
metastasis accounted for about 90% of total lung mass.  All dose levels provided about 2-91 
fold prolongation of the survival time of mice compared with the control group (mean±SD: 92 
83.3±0.88 and 40.0±0.57 days in AL-treated and control group, respectively). 93 
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Lines of evidence have suggested that either anti-angiogenic or apoptotic-related 94 
activity or both, might at least in part contribute to cytotoxic activity of AL.  Tsuneki et al. 95 
[16] investigated the anti-angiogenic activity of  β-eudesmol, the main constituent of AL, 96 
both in vitro and in vivo.  The proliferation of various endothelial cells including porcine 97 
brain microvascular endothelial cells (PBMEC) derived from cerebral microvessel, human 98 
dermal microvascular endothelial cells (HDMEC) derived from peripheral microvessels, 99 
and human umbilical vein endothelial cells (HUVEC) derived from peripheral veins, were 100 
markedly inhibited by β-eudesmol at concentrations ranging from 50 to 100 µM.  101 
Moreover, β-eudesmol also showed a broad spectrum of anti-angiogenic effects not only 102 
on blockade of the phosphorylation of extracellular signal-related kinase (ERK) 1/2 103 
induced by basic fibroblast growth factor (bFGF) or vascular endothelial growth factor 104 
(VEGF), but also on prevention of endothelial tube formation and inhibition of cell 105 
migration stimulated by bFGF.  In animal model, β-eudesmol significantly inhibited 106 
angiogenesis of subcutaneously implanted Matrigel plugs in mice and adjuvant-induced 107 
granuloma in mice [16].  These results were consistent with the observations by Ma et al.  108 
[17], showing an inhibitory effect of β-eudesmol (50-100 µM) in HUVEC induced by VEGF 109 
and bFGF.  Apart from HUVEC, Hela (human cervical cells), the proliferation of SGC-110 
7901 (human gastric cancer cells), and BEL-7402 (human liver cancer cells) were also 111 
inhibited by β-eudesmol (10-100 µM) in a time- and dose-dependent manner.  112 
Furthermore, β-eudesmol (2.5-5 mg/kg) significantly inhibited tumor growth in mice 113 
implanted with H22 and S180 tumor cells and also obviously inhibited vascular index 114 
(calculated by carmine content in the tumor tissues divided by tumor tissue weight) [17].  115 
Recently, Zhao et al. [18] demonstrated that AL extract inhibited the growth of human 116 
gastric cancer cells in a dose- and time-dependent manner, and proposed that the 117 
cytotoxic mechanism of AL was related to apoptosis and cell cycle arrest through 118 
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mitochondria-dependent and death receptor-dependent apoptotic pathways.  Further 119 
investigation should be focused on the mechanism of action of anticancer property of AL 120 
in CCA, identification of its active constituents, as well as confirmation of its clinical 121 
efficacy and safety in CCA patients. 122 
2.2 Pharmacological activities on nervous system 123 
Although neither serious adverse effect on central nervous system (CNS) nor any 124 
morbidity has been reported in human so far, the use of AL in human should be with 125 
caution in patients with nervous problems due to its various effects on nervous system.  126 
The pharmacological activity of the rhizome extract of AL on central nervous system has 127 
been demonstrated in various animal models with regards to its effects on general 128 
behavior and spontaneous movement, anti-electroshock convulsion, and potentiation of 129 
hypnotic action of hexobarbital sodium [19].  AL extract at the highest dose of 5,000 130 
mg/kg body weight significantly interfered with muscle relaxation in mice similar to that 131 
produced by the reference drug diazepam (4 mg/kg body weight) [15].  The acetone 132 
extract of AL rhizome also showed an anti-anoxic effect in potassium cyanide (KCN)-133 
induced anoxia in mice [20].  Nine out of ten (90%) mice treated with the AL extract at the 134 
dose of 1,500 mg/kg body weight survived, while none in the control group survived 135 
(0/10: 0%).  The anti-anoxic action of AL rhizome extract was shown to be due mainly to 136 
its active constituent β-eudesmol.  Six out of ten mice (60%) treated with β-eudesmol at 137 
the dose of 300 mg/kg body weight survived, whereas none in control group survived 138 
(0/10: 0%).   139 
The effect on post-synaptic neuromuscular junction (NMJ) of β-eudesmol was 140 
shown to be primarily through the blockage of nicotinic acetylcholine receptors (nAChR) 141 
via accelerated desensitization [21-23].  The potentiating effect of β-eudesmol on NMJ 142 
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was greater in diabetic than in normal muscles [24,25].  β-eudesmol has been proposed 143 
as a promising compound for potentiating neuronal function.  It was shown to induce 144 
neurite outgrowth from rat pheochromocytoma cells (PC-12) via mitogen-activated protein 145 
kinase (MAPK) activation [26]. 146 
2.3 Pharmacological activities on cardiovascular system 147 
AL extract at the dose levels of 1,000, 3,000, and 5,000 mg/kg body weight 148 
significantly reduced the heart rate of rats, but only the highest dose (5,000 mg/kg body 149 
weight) significantly decreased both systolic and diastolic blood pressure [15].  However, 150 
the mechanism of the anti-hypertensive effect of AL is still unknown.  The anti-platelet 151 
activity of AL has been demonstrated in collagen-induced platelet aggregation model [27].  152 
Since it did not inhibit adrenaline/ADP- or adrenaline/5-HT-induced platelet aggregation, 153 
its mechanism of action has been thought to be via suppression of collagen-induced 154 
signal pathway, the upstream of the release of thromboxane A2 (TXA2) from platelets.  155 
Altogether, results suggest that care should be taken when using AL extract or its active 156 
constituents in patients with platelet disorders or coagulopathy. 157 
2.4 Pharmacological activities on gastrointestinal system 158 
The pharmacological effects of AL and its constituents on gastrointestinal system 159 
support their clinical use for alleviation of digestive symptoms in traditional medicine.  AL 160 
extract has been shown to delay gastric emptying and stimulate small intestinal motility.  161 
The mechanisms of its action on these activities could be through either the inhibition of 162 
both dopamine D2 and 5-HT3 receptors [28], or activation of vagal tone and inhibition of 163 
corticotropin-releasing factor (CRF) [29].  The main activity was shown to be due to the 164 
atractylodin component [30]. 165 
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AL extract at the dose levels of 1,000, 3,000, and 5,000 mg/kg body weight 166 
produced an anti-ulcer effect at similar potency as the reference drug omeprazole given 167 
at a dose of 20 mg/kg body weight [15].  Results from a previous study in pylorus-ligated 168 
rats suggest that the mechanism of action of AL extract on anti-ulcer activity might be 169 
mediated through inhibition of gastric secretion and reduction of effects on histamine-170 
induced ulceration and stress-induced ulceration [31].  β-eudesmol is thought to be an 171 
active compound which exerts inhibitory effect on gastric secretion stimulated by 172 
histamine.  The compound could prevent gastric ulceration as effectively as cimetidine at 173 
the same dose level (10 mg/kg body weight) [32].  Apart from β-eudesmol, the anti-ulcer 174 
activity of AL was also shown with hinesol, another main constituent in AL extract at the 175 
dose of 100 mg/kg body weight.  Further investigation should be performed to elucidate 176 
the mechanisms of action of AL and its constituents on gastrointestinal system.   177 
2.5 Other pharmacological activities 178 
The anti-inflammatory activity of AL might be due to the contribution of several of 179 
its active constituents through various mechanisms.  The lipophilic extract from AL 180 
rhizome exhibited potent inhibitory effect against 5-lipoxygenase (5-LOX) and 181 
cyclooxygenase-1 (COX-1) with IC50 of 2.9 and 30.5 µg/ml, respectively [33].  Isolated 182 
compound that exhibited potent inhibitory activities against both enzymes was shown to 183 
be atractylochromene (IC50 for 5-LOX and COX-1 = 0.6 and 3.3 µM, respectively).  184 
Despite relatively low potency on COX-1 (IC50 = 64.3 µM), quinone, another isolated 185 
compound, showed a selective inhibitory activity against 5-LOX (IC50 = 0.2 µM).  186 
Atractylone also exhibited inhibitory effects against 5-LOX but with potency about 100-187 
fold lower than quinone (IC50 = 25.1 µM).  The study conducted by Seo et al. [34] 188 
demonstrated that the anti-inflammatory effect of β-eudesmol was via regulation of 189 
interleukin (IL-6) production and expression through regulation of the p38 MAPK and 190 
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nuclear factor (NF)-κB.  In addition, it also suppressed receptor-interacting protein 2 191 
(RIP2)/caspase-1 activation induced by phorbol 12-myristate 13-acetate calcium 192 
ionophore A23187 (PMACI).   193 
The antimicrobial activity of AL against various micro-organisms has been 194 
demonstrated in various studies including Staphylococcus aureus [35], Escherichia coli 195 
[35,36], Saccharomyces cerevisiae, and Candida albicans [36].  Moreover, the growth of 196 
some fungi species, such as Rhodotorula glutinis and Saprolegnia, was also inhibited by 197 
the volatile oil extract of AL.  The activity on Rhizopus and Absidia was however, 198 
relatively weak [37].   199 
Although AL extract did not produce any significant central or peripheral analgesic 200 
effects, it was shown to produce an antipyretic effect at a dose of 5,000 mg/kg body 201 
weight in the rat model [15].  This antipyretic activity supports its use for relieve fever and 202 
cold as indicated in Thai traditional medicine. 203 
 204 
3. Safety profiles of Atractylodes lancea (Thunb.) DC. 205 
AL rhizome showed safety profiles in various animal models.  Following 206 
administration of AL extract at the high dose level of 5,000 mg/kg body weight in rats and 207 
mice, no significant toxicity except stomach irritation and general CNS depressant signs 208 
(reduced alertness and locomotion and diminished response to touch and balance) was 209 
observed [15].  Results from the acute and subacute toxicity tests both in rats and mice 210 
indicated safety profiles of AL in a broad range of dose levels (1,000-5,000 mg/kg body 211 
weight).   212 
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Several clinical studies of AL have been conducted in patients with different 213 
diseases/symptoms using AL in the forms of various formulations [4,38-41]; however, 214 
there has been no clinical study conducted using AL extract or its major constituents 215 
alone.  This thus signifies the needs for further investigations in clinical trials to prove 216 
their clinical efficacy and safety profiles in humans.  Despite the lack of clinical studies to 217 
directly support its safety in human, available information has indicated no serious 218 
adverse event when they were administered in humans.  Ayurved Siriraj herbal recipe 219 
Chantaleela which consists of 60.6 mg AL in each tablet (250 mg/tablet) was 220 
administered to healthy male and female volunteers at the dose of 545.4 mg of AL/day for 221 
1 day (divided into 3 doses, administered every 8 hours).  No adverse event was 222 
observed in any subject for 10 days follow-up [42].  Moreover, observational study 223 
conducted in China showed a safety profile of “Fufang Cangzhu Tang”, a Chinese herbal 224 
formula which contains 15 g Atractylodes rhizome decocted into 300 ml of liquor and 225 
separately administered orally twice a day for 8 weeks in 32 senile patients with obesity 226 
or overweight complicated with impaired glucose tolerance [43].   227 
 228 
4. Conclusion 229 
 AL rhizome has been shown to exhibit various pharmacological activities including 230 
anticancer activities, activities on nervous and gastrointestinal systems, as well as anti-231 
hypertensive, anti-platelet, anti-ulcer, anti-inflammatory, antimicrobial, and antipyretic 232 
activities.  Despite extensive use with positive impression, there has not been a clinical 233 
study that can conclusively support its efficacy and safety profile.  Further investigations 234 
should focus on the application of AL in patients with different diseases/symptoms.  In 235 
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addition, more investigation is required to identify the specific mechanisms of certain 236 
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Figure 1.The chemical structures of major components of Atractylodes lancea (Thunb.) 363 
DC.  364 
365 
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Model  Active ingredient Mechanism of action Reference 
Anti-tumour activities 
 
Cytotoxic activity In vitro 50% Ethanol extract 50 µg/ml   [12] 
 
In vitro 50% Ethanol extract 50 µg/ml   [14] 
 
In vitro Petroleum ether fraction, ethyl acetate 
fraction, n-butanol fraction, and water 
fraction of AL 0.0625-1 mg/ml 
 
 - Induction of cell apoptosis via the 
mitochondrial pathway 
[18] 
In vitro 100% Ethanol extract 5 mg/ml   [13] 
 





Anticancer activity Mice 50% Ethanol extract 1,000-5,000 
mg/kg 
 
  [15] 
 
Anti-angiogenic activity In vitro β-eudesmol 50 and 100 µM β-eudesmol - Inhibition of the endothelial cell proliferation 
- Suppression of DNA synthesis 
- Inhibition of endothelial cell migration 
- Inhibition of tube formation by endothelial 
cells 
- Blockage of bFGF- and VEGF-induced 
ERK1/2 activation (only at the concentration 
of 100 uM) 
- Inhibition of phosphorylation of CREB 





Mice β-eudesmol 0.90 µmol/kg β-eudesmol 
 
 [16] 
In vitro β-eudesmol 50 and 100 µM β-eudesmol - Inhibition of the growth factor signaling 
pathway by depressing activation of ERK-
MAPK 
- Suppression of CREB activation in growth 
factor signaling pathway 
 
[17] 
Mice β-eudesmol 2.5-5 mg/kg β-eudesmol  [17] 
 
In vitro 50% Ethanol extract 25-100 µg/ml   [14] 
 
Anti-clonogenic activity In vitro 50% Ethanol extract 12.5-50 µg/ml   [14] 
 
Inhibitory activity on cell 
invasion 
 
In vitro 50% Ethanol extract 12.5-150 µg/ml   [14] 
 
Pharmacological activities on nervous system 
 21 
 
NMJ blocking activity Ex vivo β-eudesmol 200 µM β-eudesmol - Blockade of nicotinic ACh receptors by 
accelerating the desensitization of the 
nicotinic ACh receptor 
 
[21] 
Ex vivo β-eudesmol 20 µM β-eudesmol - Blockade of closed state of nicotinic ACh 
receptors by accelerating the desensitization 
of the nicotinic ACh receptor  
 
[23] 
Ex vivo β-eudesmol 20 µM β-eudesmol - Depression of the regenerative release of 
ACh during repetitive stimulation 
 
[22] 
Ex vivo β-eudesmol 80 µM β-eudesmol 
 
 [25] 
CNS activity on 
neuronal differentiation 
 
In vitro β-eudesmol 100 and 150 µM β-eudesmol - Induction of neurite outgrowth mediated by 
MAPK activation 
[26] 






Mice 50% Ethanol extract 5,000 mg/kg   [15] 
CNS depressant activity Mice Benzene extract 200-1,000  mg/kg 
 
  [19] 




Rats 50% Ethanol extract 5,000 mg/kg 
 
  [15] 
Anti-platelet activity In vitro Crude extract 30-1,000 µg/ml  - Inhibition of collagen-induced signal 
pathway, which is upstream of the release of 
TXA2 from platelets 
 
[27] 
Pharmacological activities on gastrointestinal system 
 
Anti-ulcer activity Rats 50% Ethanol extract 1,000-5,000 
mg/kg 
  [15] 
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Rats Benzene extract 500 mg/kg 
 
  [19] 












Improvement of the 
delayed gastric 
emptying 
Rats Ethanol extract 30-120 mg/kg  - Inhibition of the CRF release  
- Activation of vagal pathway  
- Involvement in the release of 
gastrointestinal hormones such as motilin, 




Rats Water extract 250 mg/kg and 
Atractylodin and its derivatives 0.1-0.3 
mg/kg 
 





Mice Water extract 500-1,000 mg/kg and β-
eudesmol 50-100 mg/kg 
 
 β-eudesmol - Inhibition of the dopamine D2 receptor and 
the 5-HT3 receptor 
[28] 




Rats 50% Ethanol extract 5,000 mg/kg 
 
  [15] 
In vitro β-eudesmol 2, 20 µM β-eudesmol - Regulation of IL-6 through regulation of the 
p38 MAPK and NF-κB 




In vitro  Atractylochromene, 
Quinone, Atractylon 
Inhibition against 5-LOX and COX-1 [33] 
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Mice Atractylenolide I 300 mg/kg Atractylenolide I 
 
 [45] 
Antipyretic activity Rats 50% Ethanol extract 5,000 mg/kg 
 
  [15] 
Antimicrobial activity  
- against E. coli, S. 
cerevisiae, and C. albicans 
In vitro 95% Ethanol extract 200 mg/ml 
 
  [36] 








In vitro    [37] 
 
 
AL, Atractylodes lancea; bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; ERK, extracellular signal-regulated kinase; CREB, 
cyclic adenosine monophosphate (cAMP) response element binding protein; NMJ, neuromuscular junction; ACh, acetylcholine; TXA2, thromboxane A2; CRF, 
 26 
Corticotropin-releasing factor; IL, interleukin; MAPK, mitogen-activated protein kinase; NK-κB, nuclear factor-κB; RIP2, receptor-interacting protein 2; LOX, 
lipoxygenase; COX, cyclo-oxygenase.
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